Company intelligence / Profile preview
Destiny Pharma
Brighton, England, United Kingdomdestinypharma.com ↗
- Ownership
- Private
- Employees
- ~15
- Development stage
- Phase 3
01
Overview
Destiny Pharma has two late-stage clinical programs. The lead asset, XF‑73 Nasal Gel, achieved its primary endpoint in a Phase IIb trial by reducing nasal S. aureus bacterial load by over 99% compared to placebo with an excellent safety profile and no treatment-related adverse events. However, the company has struggled to secure a partner or funding for Phase III trials due to high anticipated costs and market challenges for antibiotics. Its second late-stage asset, NTCD-M3—a microbiome therapeutic—targets prevention of C. difficile infection recurrence.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecules (e.g., XF platform synthetic porphyrins)Microbiome-based biotherapeutics (e.g., NTCD-M3)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
CMS China partnership for development/commercialization in China regionseeking additional partners globally
Beyond the preview
Go deeper on Destiny Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Destiny Pharma.